Compare Natera Inc. Common Stock (NTRA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Wells Fargo & Co — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Wells Fargo & Co trades at $81.36 (market cap $242.35B). The key difference: Wells Fargo & Co is far larger — about 4.2× Natera Inc. Common Stock's market cap, and Wells Fargo & Co pays a 2.48% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Wells Fargo & Co for 88 Days on average.
| NTRA | WFC | |
|---|---|---|
Market Cap | $57.03B | $242.35B |
Volume | 1,131,157 | 25,561,701 |
Sector | Health | Financials |
52-Week High | $425.64 | $96.40 |
52-Week Low | $179.42 | $73.42 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $56.18B | $424.64B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Wells Fargo (WFC) trades at $80.91, down 2.88% on the day, amid mixed technical signals with a bullish overall trend but bearish moving averages. The bank shows strong fundamentals with a P/E of 11.74, net income margin of 25.97%, and consistent earnings beats in recent quarters. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and renewed technology agreements supporting mortgage servicing.
The stock presents a value opportunity with a consensus price target of $98.75, implying 22% upside, supported by analyst bullishness (46.66% buy ratings). Key risks include volatile cash flows, with operating cash flow negative in 2025, and sensitivity to interest rate changes as highlighted by recent Fed hikes (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
